I think they have a very solid product, present in 30 countries and 8 jurisdictions. I saw this kind of performance with Novo Nordisk and I think OncoSil has a similar profile. Innovation + strong management/commercial strategy does it for me. It's going to become the new pancreatic cancer medication used everywhere. I see the current market consolidation phase as a buying strategy.
I think they have a very solid product, present in 30 countries...
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.2¢ |
Change
0.001(9.09%) |
Mkt cap ! $45.40M | |||
| Open | High | Low | Value | Volume |
| 1.1¢ | 1.2¢ | 1.1¢ | $18.92K | 1.705M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 25 | 13619110 | 1.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.2¢ | 5063491 | 9 |
View Market Depth
| Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
| OSL (ASX) Chart |